Accelerating Rheumatology Prior Authorization Automation

The Unique Challenges of Rheumatology Prior Authorization

Rheumatology presents one of the highest PA burdens across specialties, primarily due to the chronic nature of autoimmune diseases and the high cost of advanced therapeutic agents. Managing conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and lupus often involves biologics, JAK inhibitors, and infusion therapies, all of which are frequent triggers for prior authorization. This necessitates meticulous documentation, adherence to specific clinical guidelines, and continuous re-authorization processes.

Key Prior Authorization Triggers in Rheumatology

• Biologics: TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab) and non-TNF biologics (e.g., tocilizumab, secukinumab, guselkumab).
• JAK Inhibitors: Targeted synthetic DMARDs like tofacitinib, baricitinib, and upadacitinib.
• Infusion Therapy: Provider-administered biologics and other intravenous treatments.
• Specialty Drugs: Therapies for specific indications, such as anifrolumab and belimumab for SLE.
• Advanced Imaging: MRI for inflammatory arthritis assessment and ultrasound-guided joint injections.

Navigating Complex Documentation and Payer Policies

Rheumatology prior authorizations demand precise clinical documentation aligned with guidelines like the ACR Treatment Guidelines. Payers routinely require specific ICD-10 codes, detailed disease activity assessments (e.g., DAS28, CDAI, PASI/BSA), and documented trials of conventional DMARDs. Furthermore, step therapy protocols, biosimilar substitution mandates, and pre-treatment screening completion (e.g., TB, hepatitis B/C) add layers of complexity, with non-compliance being a leading cause of denials.

Common Rheumatology PA Denial Reasons Addressed by Automation

• Failure to document specific prior agent trial or step therapy completion.
• Denial for brand TNF inhibitor when a biosimilar is mandated first.
• Missing or insufficient disease activity scores (e.g., DAS28, CDAI).
• Incomplete screening documentation (e.g., TB, hepatitis, immunization status).
• Off-indication use without supporting payer-specific policy.
• Conservative care duration not meeting payer-required timelines.

Klivira's Approach to Rheumatology Prior Authorization Automation

Klivira's platform is engineered to address the specific workflow constraints of rheumatology. We integrate directly with your EMR via SMART on FHIR and CDS Hooks to detect PA requirements at the point of order entry. Our system leverages payer-specific policy engines, incorporating ACR-guideline-aware logic for step therapy sequencing and biosimilar substitution routing. This ensures that documentation is accurately assembled and submitted through the correct channel, whether via Da Vinci PAS API, X12 278, or payer portal.

End-to-End Automation for Rheumatology Workflows

Klivira automates the entire PA lifecycle, from initial requirement discovery to approval write-back and denial management. This includes automated documentation discovery from FHIR resources, intelligent routing for medical versus pharmacy benefit split for the same agent, and a specialized periodic re-authorization workflow for chronic treatments. Our system tracks timely-filing windows and facilitates appeal automation, reducing manual effort and improving decision turnaround times, consistent with standards like CMS-0057-F for impacted payers.